Journey Medical Expands Loan Facility and Strengthens Leadership
Company Announcements

Journey Medical Expands Loan Facility and Strengthens Leadership

Journey Medical Corp (DERM) just unveiled an announcement.

Journey Medical Corporation has amended its credit agreement, increasing its loan facility from $20 million to $25 million, contingent on FDA approval for its drug DFD-29 by June 30, 2025. Currently, $20 million has been drawn, with further funds available upon satisfying the approval condition. The loan, maturing in December 2027, has a repayment schedule based on the company’s revenue, with interest rates pegged to the three-month term SOFR plus 7.75%. Additionally, the company has appointed healthcare investor Michael C. Pearce to its Board of Directors and has adopted a Deferred Compensation Plan for directors and select executives, allowing for the deferral of various forms of compensation.

For a thorough assessment of DERM stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyBiotech Alert: Searches spiking for these stocks today
TheFlyJourney Medical price target raised to $11 from $8.50 at Alliance Global Partners
TheFlyJourney Medical announces U.S. FDA approval of Emrosi
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App